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Abstract
The Gram negative curved bacillus H. pylori has become the prize bug of all times. Barry Marshall
and Robin Warren the two discoverers of this organism have been awarded with this year's Nobel
Prize. The Nobel committee at the Karolinska Institute of Sweden has selected this paradigm shift
discovery of 1982 as the most impacting in medical sciences. This award has surprised many as the
Nobel assembly has selected this 'Robert Koch styled medical detective work' for the prize as
compared to many outstanding basic research stories on the waitlist. This editorial briefly touches
the significant impact of H. pylori on gastroduodenal management and the path forward as the bug
has become quite controversial in recent times.
Helicobacter pylori is a bacterium that colonizes human
stomach and is an established cause of chronic superficial
gastritis, chronic active gastritis, peptic ulcer disease and
gastric adenocarcinoma [1]. The infection is on a fast
decline in most of the western countries, mainly due to
the success of therapeutic regimens and improved per-
sonal and community hygiene that prevents re-infection.
The eradication in some of the countries has been quite
promising and the pathogen was declared as an endan-
gered bacterial species [2]. However, the situation is
exactly opposite in many of the developing countries due
to failure of treatment and emergence of drug resistance.
Barry J. Marshall and Robin Warren, two Australian
researchers who discovered the bacterium Helicobacter
pylori and deciphered its role in gastritis and peptic ulcer
disease, have been awarded this year's Nobel Prize in
Physiology or Medicine. The Nobel Assembly at the Karo-
linska Institute has honored them for their unexpected
but paradigm shift discovery [3,4] that revealed that gas-
tritis, and ulceration of the stomach or duodenum, were
the result of infection with some curved Gram negative
bacilli.
At that time when Warren and Marshall announced their
findings, it was a long-standing belief in medical teaching
and practice that stress and lifestyle factors were the major
causes of peptic ulcer disease. Warren and Marshall rebut-
ted that dogma, and it was soon clear that H. pylori, causes
more than 90% of duodenal ulcers and up to 80% of gas-
tric ulcers. The clinical community, however, met their
findings, with skepticism and a lot of criticism and that's
why it took quite a remarkable length of time for their dis-
covery to become widely accepted. They had to just push
it harder and harder with all experimental and clinical evi-
dences. In 1985, for example, Marshall underwent gastric
biopsy to put evidence that he didn't carry the bacterium,
then deliberately infected himself to show that it in fact
caused acute gastric illness. This 'self-help' experiment was
published in the Medical Journal of Australia [4] to
describe development of a mild illness over a course of 2
weeks, which included histologically proven gastritis. This
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cation and commitment to his research that generated one
of the most radical and important impacts on the last 50
year's perception of gastroduodenal pathology. Their
research made H. pylori infection one of the best-studied
paradigms of pathogen biology, paving way for intense
and hectic basic and clinical research activity leading to
about 25,000 scientific publications till date. To realize
the tremendous response of scientific and clinical com-
munities, a dedicated journal called 'Helicobacter' was
also started.
Soon the genomes of the bacilli were fully sequenced to
decipher pathogenic mechanisms. Post genomic analyses
have revealed interesting attributes of H. pylori genomic
diversity, pathogenicity and novel mechanisms of causa-
tion of ulcer disease and cancer [5]. Efforts to know the
implications of the genetic diversity of this bacterium
have led to some interesting discoveries relating to its co-
evolution with the human host, microevolution during
infection and quasi-species development. Possible symbi-
otic relationships were debated since the discovery of this
pathogen. However, the debate has been intensified since
few years as some studies have posed the possibility that
H. pylori infection may be beneficial in some humans [6-
8]. Studies [8] have suggested that H. pylori infection pro-
tects against gastro-oesophageal reflux [8] and oesopha-
geal carcinoma [9].
How long humans carried H. pylori is still a debatable
issue. However, it is accepted that this organism has colo-
nized humans possibly for many thousands of years, and
the successful persistence of H. pylori in human stomach
for such a long period may be a case to conceive that this
organism is advantageous to its host.
It has been shown that H. pylori produces a cecropin-like
peptide (antibacterial peptide) with high antimicrobial
properties [6]. Another study [7] revealed that children
infected with H. pylori were less likely to have diarrhoea
than children without an infection, implying that H. pylori
may be beneficial to human hosts. Interestingly, there has
been a marked decline in the instances of peptic ulcer dis-
ease and gastric cancer in the 20th century. Concurrent
with this is a dramatic increase in the incidences of gastro-
oesophageal reflux disease (GERD), Barrett's oesophagus
and adenocarcinoma of the oesophagus in western coun-
tries [8,9]. This observation led to the speculation that H.
pylori may in some way be associated with these diseases
and perhaps capable of preventing their onset. Studies
have also shown that cagA+ H. pylori strains have a more
protective effect than cagA - strains [10]. The presence of
cagA+ H. pylori strains can reduce the acidity of the stom-
ach, and it is believed that the raising of the pH by H.
pylori prevents GERD, Barrett's oesophagus and adenocar-
cinoma of the oesophagus. Conversely, arguments have
been made that, although H. pylori may prevent these
reflux-associated diseases, the risks of acquiring gastric
cancer via H. pylori infection far outweigh any possible
benefits it may provide [11]. In spite of this controversy,
recent reports have demonstrated a protective role for H.
pylori in erosive reflux oesophagitis [11,12]. However, as
safe and potent anitsecretory drugs are available it seems
foolish to use a dangerous organism that has been associ-
ated with extremely dangerous outcomes such as a carci-
noma.
In my opinion, the intricacies of the role of H. pylori in
health and disease may be fully known only if we analyze
pathogen biology as juxtaposed to the host biology and
the environment (food and dietary habits). Cancer of
stomach is a highly lethal disease and establishment of H.
pylori as a risk factor for this malignancy deserves an
approach to identify persons at increased risk; however,
infection with this organism is extremely common and
most colonized persons never develop cancer. The
research activities should focus this reality, and identify
populations that never develop gastric cancers despite
heavy infection rates. Indians for example rarely develop
gastric cancer; the incidence is extremely low or negligible
(the age adjusted rates being extremely low, about 3 per
100, 000) [13] as compared to populations such as Japa-
nese. This brings into debate a third dimension that is
environment (diet? and lifestyle) that has not been
explored as intensely as the pathogen virulence factors.
While many researchers are now convinced that the path-
ological outcomes of H. pylori infection are far more dam-
aging than any beneficial effects of its inhabitation, there
are enough strong evidences that absence of H. pylori from
the stomach may lead to cancers of other gut regions.
Therefore, there is an urgent need to thoroughly assess
risks and benefits of H. pylori and the role of chronic infec-
tion in the development of cancers of gut and to provide
for a basis to launch global strategies to fight this problem
and settle the debate.
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